[ONTX] Onconova Therapeutics, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ONTX
ONTX is in the medium-term down -74% in 4 months. In the long-term up 210891% in 18 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -8.8% | Sales Growth - Q/Q | 0% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -156.2% | ROE | -487.72% | ROI | ||
| Current Ratio | 3.38 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.92 | ||
| Gross Margin | Operating Margin | -12282.7% | Net Profit Margin | -12279.7% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | -9.85 M | Gross Profit | |||
| Net Profit | -12.34 M | Operating Profit | -12.35 M | Total Assets | 36.71 M | Total Current Assets | 36.35 M |
| Total Current Liabilities | 10.76 M | Total Debt | Total Liabilities | 24.95 M | Total Revenue | 110 K |
Technical Data
| High 52 week | 10.59 | Low 52 week | 0.35 | Last close | 2.61 | Last change | -0.76% |
| RSI | 18.75 | Average true range | 0.39 | Beta | 0.12 | Volume | 18.76 K |
| Simple moving average 20 days | -27.21% | Simple moving average 50 days | -44.2% | Simple moving average 200 days | -42.94% |
Performance Data
| Performance Week | -23.46% | Performance Month | -40.41% | Performance Quart | -63.03% | Performance Half | -66.75% |
| Performance Year | 78.77% | Performance Year-to-date | 74% | Volatility daily | 6.4% | Volatility weekly | 14.31% |
| Volatility monthly | 29.33% | Volatility yearly | 101.59% | Relative Volume | 157.7% | Average Volume | 276.28 K |
| New High | New Low |
News
2019-01-16 13:08:04 | Bucks County biopharm firm names new CEO
2019-01-15 17:15:00 | Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
2019-01-02 07:30:00 | Onconova Submits Special Protocol Assessment SPA to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine Vidaza® for First-Line Myelodysplastic Syndromes MDS
2018-12-31 07:30:00 | Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
2018-12-10 07:30:00 | Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
2018-12-03 07:30:00 | Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine Vidaza® in Myelodysplastic Syndromes MDS at the 2018 ASH Annual Meeting
2018-11-13 15:41:27 | Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT
2018-11-13 07:00:00 | Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018
2018-11-07 08:30:00 | Onconova Welcomes Richard Ric Woodman, M.D., as Chief Medical Officer CMO
2018-11-06 10:30:03 | Onconova Therapeutics ONTX May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2018-11-05 08:30:00 | Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes MDS at the 2018 ASH Annual Meeting & Exposition
2018-11-01 08:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results
2018-10-29 08:30:00 | Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark
2018-10-17 08:30:00 | Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib
2018-10-10 08:30:00 | Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco
2018-09-27 08:00:00 | Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences
2018-09-26 12:12:17 | Bucks County biopharm firm implements reverse stock split
2018-09-25 09:16:13 | Onconova Therapeutics Announces Reverse Stock Split
2018-08-21 08:30:00 | Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes MDS to South America with Pint Pharma
2018-08-15 10:05:53 | Edited Transcript of ONTX earnings conference call or presentation 14-Aug-18 1:00pm GMT
2018-08-14 08:00:00 | Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018
2018-08-14 07:00:00 | Onconova Therapeutics Inc. to Host Earnings Call
2018-08-07 08:00:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results
2018-07-17 07:25:00 | Free Technical Research on OPKO Health and Three More Biotech Equities
2018-06-21 08:00:00 | Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D.
2018-06-07 08:30:00 | Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association
2018-05-29 08:00:00 | Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational
2018-05-25 19:21:18 | Who Are The Top Investors In Onconova Therapeutics Inc NASDAQ:ONTX?
2018-05-22 07:00:00 | Free Technical Insights on OPKO Health and Three Other Biotech Stocks
2018-05-15 18:30:54 | Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT
2018-05-15 08:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018
2018-05-15 07:31:13 | Analysts Expect Breakeven For Onconova Therapeutics Inc NASDAQ:ONTX
2018-05-09 08:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results
2018-05-03 08:00:00 | Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018
2018-05-01 20:10:14 | Onconova Therapeutics Inc NASDAQ:ONTX: Does The Earnings Decline Make It An Underperformer?
2018-05-01 18:33:47 | Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering
2018-04-27 06:00:00 | Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering
2018-04-19 08:30:00 | Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
2018-03-15 08:00:00 | Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
2018-03-09 12:13:37 | Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT
2018-03-08 08:00:00 | Onconova Therapeutics Inc. to Host Earnings Call
2018-03-06 08:30:00 | Onconova Therapeutics to Present at the 30th Annual Roth Conference in March
2018-03-05 08:00:00 | Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America
2018-03-04 10:00:00 | Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research AACR Epigenetics Conference
2018-03-01 12:00:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2017 Financial Results
2018-03-01 08:00:00 | Onconova to Present Dose Optimization Studies with Rigosertib Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium
2018-02-20 08:30:00 | Onconova Announces Two Presentations at 2018 American Chemical Society National Meeting and Expo
2018-02-12 15:55:00 | Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Securities
2018-02-08 06:00:00 | Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering